Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

908.46 +3.49 (+0.39%)
Streaming Delayed Price Updated: 10:25 AM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
Market Thoughts This Labor Day Weekend
For this long weekend, I am offering you food for thought. In the overall macro theme, I am sticking to this for time being: Stagflation - The Fed can’t fix it with a huge reduction in rates, that will... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Gilding The Lilly
Via Talk Markets
S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points
While the Nasdaq lagged last week, the S&P 500 entered a power trend Friday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy in September
There's at least one key common denominator here: tremendous growth prospects. 
Via The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
This competitive showdown just saw one of the players hit a couple of bumps. 
Via The Motley Fool
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
Via Benzinga
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $1,000
Business is booming for these stocks. 
Via The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
A Philadelphia judge's early ruling in the Ozempic and Wegovy litigation may shape the outcome of the lawsuits against Novo Nordisk and Eli Lilly, focusing on the diagnosis of gastroparesis and the... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Novo Nordisk's semaglutide reduced the risk of cardiovascular events in heart failure patients by 31% in recent trials published by The Lancet. While not approved for heart failure outcomes in the US,... 
Via Benzinga
Think Eli Lilly Stock Has Peaked? These 10 Words From the CEO May Change Your Mind
Eli Lilly may not be an expensive stock when you consider its long-run growth prospects. 
Via The Motley Fool
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
The addressable market for the treatments could potentially contract significantly. 
Via The Motley Fool
Why Hims & Hers Health Stock Was Falling This Week
A new threat from Eli Lilly pushed the stock lower. 
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem. 
Via The Motley Fool
Warren Buffett's Berkshire Hathaway Breaks $1 Trillion: Poll Suggests Big Pharma, Not Tech, Is Next Contender
Warren Buffett is now the leader of a $1 trillion company with Berkshire Hathaway passing the milestone in August 2024 and joining an elite club. 
Via Benzinga
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
It'll be a while before there's any impact, but it could be a big deal. 
Via The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space. 
Via Benzinga
Why Viking Therapeutics Stock Got Thrashed on Tuesday
A monster rival is making aggressive moves in one particular segment. 
Via The Motley Fool
Why Hims & Hers Stock Crashed on Tuesday
Could a competitor lowering prices eat into Hims & Hers market share? 
Via The Motley Fool
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
Why Hims & Hers Health Stock Is Falling
Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has raised concerns over increased competition and potential market share loss. 
Via Benzinga
Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.
Its rock-star therapy looks like it could be marketed as a preventative treatment. 
Via The Motley Fool
Eli Lilly Slashes Zepbound Weight Loss Vial Prices By Up To 50% To Boost Access
Eli Lilly launches low-dose Zepbound vials for weight loss, offering 2.5 mg and 5 mg options for self-pay patients. These vials, priced at a significant discount compared to other GLP-1 obesity drugs,... 
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Shareholders don't have too much to fear -- yet. 
Via The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited... 
Via Benzinga
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.